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2Summary
Background and purpose
Astrocytes of the mouse neocortex express functional NMDA receptors which are not blocked by
Mg2+ions. However, study of the pharmacological profile of glial NMDARs and their subunit composition
is far from complete.
Experimental approach
In the present study we tested the sensitivity of NMDA receptor-mediated currents in the cortical
astrocytes and neurons to the novel GluN2C/D subunit-selective antagonist UBP141. We also examined
the action of memantine, an antagonist reported to have substantially different affinities for GluN2A/B
and GluN2C/D-containing receptors in physiological concentrations of extracellular Mg2+.
Key results
UBP141 had a strong inhibitory action on NMDA receptor-mediated transmembrane currents in the
cortical layer II/III astrocytes with an IC50 of 2.29 µM and a modest inhibitory action on NMDA-responses
in the pyramidal neurons with IC50 of 19.8 µM. Astroglial and neuronal NMDA receptors exhibited
different sensitivities to memantine with corresponding IC50 of 2.19 and 10.8 µM, respectively.
Consistent with pharmacological differences between astroglial and neuronal NMDA receptors, NMDA
receptors in astrocytes showed lower Ca2+-permeability than neuronal ones with PCa/PNa ratio of 3.4.
Conclusions and Implications
The combination of biophysical and pharmacological properties of astrocytic NMDA receptors strongly
suggests they have tri-heteromeric structure composed of GluN1, GluN2C/D and GluN3 subunits.
Dramatic difference between astroglial and neuronal NMDA receptors in their sensitivity to UBP141 and
memantine may enable selective modulation of astrocytic signalling that could be very helpful for
3elucidating the mechanisms of neuron-glia communications. Our results may also provide a clue for
development novel therapeutic agents specifically targeting glial signalling.
Keywords: Memantine; UBP141; NMDA receptor; GluN3A subunit; calcium permeability; neuron-glia
communication; GluN3B; mouse cortex.
4Introduction
N-methyl-D-aspartate receptors (NMDARs) are the most complex glutamate-gated ionotropic receptor
in the CNS. They play a key role in the excitatory synaptic transmission and many brain functions, such
as memory and cognition. Because of their involvement in various brain pathologies, including ischemia,
neurodegenerative and neuropsychiatric disorders, NMDA receptors attract a great deal of interest in
therapeutic research (Lipton, 2006; Paoletti and Neyton, 2007).
There is a great diversity in the NMDAR subtypes. It is widely accepted that functional NMDARs
are tetrameric complexes assembled of the two obligatory GluN1 subunits combined with one or two
GluN2(A,B,CD) and/or GluN3(A,B) subunits (Matsuda et al., 2003; Furukawa et al., 2005; Paoletti and
Neyton, 2007). Subunit composition determines specific pharmacological and biophysical properties of
NMDARs such as glutamate affinity, receptor desensitization, pharmacological sensitivity, and channel
block by extracellular Mg2+ (Cull-Candy and Leszkiewicz, 2004; Paoletti and Neyton, 2007). GluN2 and
GluN3 subunit expression exhibits regional specificity and undergoes developmental regulation (Monyer
et al., 1994; Cull-Candy and Leszkiewicz, 2004; Paoletti and Neyton, 2007; Henson 2010).
Until recently, attention has been focused on the role of NMDARs in neuronal function. The
functional expression of NMDA receptors in glia was unappreciated for a long time. Because of the
voltage-dependent Mg2+-block, NMDA receptors were expected to be inactive at physiological resting
potential in non-excitable glial cells. It has been reported only recently that glial cells, namely
oligodendrocytes (Karadottir et al., 2005; Micu et al., 2006) and cortical astrocytes (Lalo et el., 2006),
express functional NMDA receptors that have distinct biophysical properties and may be composed of
subunits different from GluN2A and GluN2B. Most importantly, glial NMDARs exhibit the weak Mg2+-
block at physiological concentrations (Karadottir et al., 2005; Lalo et al. 2006) and therefore can be
5active even at resting membrane potential. We have previously shown that astroglial NMDA receptors
mediate transmembrane currents in cortical astrocytes activated upon physiological synaptic
transmission (Lalo et el., 2006).
Recent studies linking glial NMDARs to various neurological disorders ignited an interest in them as
promising targets for the development of new therapeutic agents (Lipton, 2006; Matute et al., 2006).
Finding specific antagonists of astroglial NMDAR receptors could allow the selective modulation of
astroglial signaling without directly affecting neurons. This would be very useful for the investigation of
the mechanisms of astroglial modulation of synaptic transmission and plasticity. However, study of the
pharmacological profile of glial NMDARs is far from complete.
We tested the sensitivity of astroglial NMDARs to the novel antagonist UBP141 reportedly
exhibiting selectivity over different GluN2 subunits (Morley et al., 2005; Brothwell et al., 2008). We also
tested the action of memantine – a therapeutically used antagonist which was reported to have
substantially different affinity for GluN2A/B and GluN2C/D-containing receptors in physiological
concentrations of extracellular Mg2+ (Kotermanski and Johnson, 2009).
Methods
Slice and cell preparation
Experiments were performed on transgenic mice expressing enhanced green fluorescent protein (EGFP)
under the control of the human glial fibrillary acidic protein (GFAP) promoter (line TgN(GFAP-EGFP)GFEC-
FKi; see Nolte et al., 2001; Lalo et al., 2006). Mice (4 - 8 weeks old) were anaesthetized by halothane
(1.5-1.8 vol %) and then decapitated, in accordance with UK legislation. Slices were prepared using the
technique described previously (Lalo et al., 2006). Brains were rapidly dissected in physiological saline
containing (in mM): 135 NaCl, 3 KCl, 3 MgCl2, 0.5 CaCl2, 26 NaHCO3, 1 NaH2PO4, 15 glucose, pH 7.4 when
gassed with
695% O2 / 5%CO2. Brain slices (280 - 300 µm thick) were cut at 4
o C and kept at room temperature for 1 -
4 h prior to in situ recordings and cell isolation in the above solution but with (mM) CaCl2 2.5 , MgCl2 1.
The same extracellular solution was used for recordings in slices.
Astrocytes and neurons were acutely isolated from somatosensory cortex layer II/III using the modified
“vibrating ball” technique (Pankratov et al., 2002; Lalo et al., 2006). The glass ball (200 µm diameter)
was moved slowly some 10 - 50 µm above the slice surface, while vibrating at 100 Hz (lateral
displacements 20 - 30 µm). The composition of external solution for isolated cell experiments was (mM):
135 NaCl; 2.7 KCl; 2 CaCl2; 1 MgCl2; 10 HEPES, 1 NaH2PO4, 15 glucose, pH adjusted with NaOH to 7.3. In
some experiments, the extracellular CaCl2 concentration was elevated to 20 mM.
Electrophysiology
Cells were initially identified by size and the shape of somata under IR gradient contrast and green
fluorescence (astrocytes). After establishing the whole-cell recording configuration, identification of
cells was verified by their response to a series of depolarizing and hyperpolarizing voltage steps from a
holding potential of -80 mV (Lalo et al., 2006). All cells identified visually by EGFP fluorescence
demonstrated an electrophysiological signature characteristic of astrocytes, i.e series of passive currents
with nearly linear I-V relationship, whereas cells identified as pyramidal neurons exhibited prominent
rapidly-activating currents elicited by depolarization as described previously in (Lalo et al., 2006).
Whole-cell voltage clamp recordings from the cortical astrocytes and pyramidal neurons were made
with patch pipettes (5 - 6 M) filled with intracellular solution (in mM): 110 KCl, 12 NaCl, 10 HEPES, 5
MgATP, 0.2 EGTA, pH 7.35. The membrane potential was clamped at -80 mV in the astrocytes and at -40
mV in the neurons unless stated otherwise. Currents were monitored using an AxoPatch200B patch-
clamp amplifier (Axon Instruments) filtered at 2 kHz and digitized at 4 kHz. Experiments were controlled
7by PCI-6229 data acquisition board (National Instruments) and WinFluor software (Strathclyde
Electrophysiology Software); data were analyzed by custom-designed software.
Liquid junction potentials were measured with the patch-clamp amplifier; all voltages reported were
corrected accordingly. Series resistances were 5-12 M and input resistances were 50-150 MΩ for 
astrocytes and 400-900 MΩ for neurons; both varied by less than 20% in the cells accepted for analysis. 
A modified “square-pulse” concentration jump method (Pankratov et al., 2002; Lalo et al., 2006) was
used for rapid applications of solutions containing various agents to the acutely isolated cells. Unless
stated otherwise, transmembrane currents were evoked in acutely isolated cortical neurons and
astrocytes by application of 50 µM NMDA and 1µM glycine. Antagonists of NMDA receptors were pre-
applied for 2 min before application of agonist. Between agonist applications, cells were constantly
perfused with agonist-free extracellular solution using gravity-fed bath application (flow rate 1-1.5 ml
min-1). Responses of the cortical neurons and astrocytes to glycine were recorded in presence of 10 μM 
strychnine and 100 μM picrotoxin. 
To examine the synaptic currents in situ, voltage-clamp recordings were made from identified astrocytes
and pyramidal neurons situated in the somatosensory cortex layer II/III at temperature of 30-320C.
Axons originating from layer IV-VI neurones were stimulated at 0.15 Hz with a bipolar coaxial electrode
(WPI, USA) placed in the layer IV approximately opposite the site of recording. Stimuli were single pulses
(300 µs) of magnitude adjusted to produce a synaptic current in neurons that was 30-40% of the
maximal response (typically, stimulus amplitude was 5–7 μA). At such stimulus strength the amplitude 
of response in the astrocytes reached 25-30% of maximal.
8To isolate the NMDA receptor-mediated components of glial and neuronal currents activated by
synaptic stimulation, cortical slices were treated with the following pharmacological agents: picrotoxin
100 µM, a combination of the inhibitors of glutamate transporters (Danbolt, 2001; Hu et al., 2003) (3S)-
3-4-(Trifluoromethyl)benzoyl]amino]phenyl]methoxy-L-aspartic acid (TFB-TBOA),  1 μM and DL-threo-b-
Benzyloxyaspartic acid (DL-TBOA), 30 µM; an antagonist of AMPA receptors, 6-Cyano-7-
nitroquinoxaline-2,3-dione (CNQX), 50 µM; the P2X receptor antagonist pyridoxalphosphate-6-
azophenyl-2',4'-disulfonic acid tetrasodium salt (PPADS), 30 µM. According to our previous reports (Lalo,
et al. 2006; Lalo et al., 2008) these concentrations of antagonists effectively inhibited P2X, AMPA
receptors and glutamate transporters expressed in the cortical astrocytes and neurons.
Fluorescent Ca2+-imaging
To monitor intracellular Ca2+, cortical astrocytes were loaded with 150 µM Fluo-3 through the whole-cell
patch-pipette (substituting the EGTA in the intracellular saline). Cells were illuminated at 495 nm using
the OptoScan monochromator (Cairn, UK), fluorescence was measured at 530±20 nm.
The fluorescent images were recorded using an Olympus BX51 microscope with an UMPLFL20X/NA0.95
objective and 2X intermediate magnification and an iXon885 EMCCD camera (Andor Technology, UK);
exposure time was 35 ms at 2X2 binning. Elevation in the intracellular Ca2+ level was evaluated by ΔF/F0
ratio after background subtraction.
Data analysis
Data on the concentration-dependence of the effects of antagonists were fitted with the following:
I/I0 = 1/(1+([B]/IC50)
p), where I is the current measured with drug concentration [B], I0 is the current in
control conditions, and p is a Hill coefficient. The relative calcium permeability of NMDA receptors was
calculated from the reversal potential of NMDA-activated current in the context of the extended
Goldman-Hodgkin-Katz theory as described previously (Lewis 1979; Mayer and Westbrook, 1987;
9Pankratov et al., 2002). Briefly, the current-voltage relationships of NMDA-response were normalised to
the amplitude at -40 mV, averaged over all cells and fitted with a polynomial curve to determine a
reversal potential. The permeability ratios for Ca2+ to Na+ (PCa/PNa) and Na
+ to K+ (PNa/PK) were
calculated from values of reversal potential at two different extracellular calcium concentrations
converted to the activities in the electrolyte solutions (Mayer and Westbrook, 1987; Castro and
Albuquerque, 1995); the following activity coefficients were used: 0.77 for Na+ and K+, 0.29 and 0.26 for
low and high concentrations of Ca2+.
Drugs
UBP141 was purchased from Ascent Scientific (UK), other receptor antagonists were from the Tocris
Bioscience, other salts and chemicals were from Sigma (Dorset, UK).
Results
Agonist-evoked currents in acutely isolated astrocytes and neurons
Recordings from visually-identified acutely isolated fluorescent astrocytes were made within 20–50 min
after isolation. Taking into account the competitive mechanism of UBP141 action (Morley et al., 2005)
we activated astrocytic NMDA receptors by saturating concentration of NMDA (50µM, see Lalo et al.,
2006; Erreger et al., 2007). Application of 50 µM NMDA with 1µM glycine at a holding potential -80 mV
(in 1 mM extracellular Mg2+) evoked inward currents in all of 58 astrocytes tested (Fig.1A). Functional
properties of NMDA-activated currents, i.e slow desensitization kinetics, high affinity to agonist,
sensitivity to D-AP5 and lack of Mg2+ block were similar to our data reported previously for cortical
astrocytes (Lalo et al., 2006, see also Fig.4A). Contrary to the astrocytes, L2/3 pyramidal neurons did not
respond to NMDA at holding potential of –80 mV due to Mg2+-block; currents elicited by NMDA in the
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pyramidal neurons at other holding potentials had functional properties very similar to NMDA receptors
in hippocampal and cortical neurons (Mayer and Westbrook, 1987; Lalo et al.,2006, see also Fig.4B).
Unless stated otherwise, all experiments reported below were carried out at holding potential -80 mV in
astrocytes and at -40 mV in neurons.
UBP141, novel subunit-selective antagonist of NMDA receptors, had different inhibitory action in
astrocytes and neurons (Fig.1). Pre-incubation with 3 µM UBP141 for 2 min decreased the amplitude of
NMDA-evoked responses (Fig.1A) in the astrocytes by 62 ± 14% (n=7) whereas neuronal responses
(Fig.1B) were inhibited by only 9±11% (n=6). The action of UBP141 was reversible in both astrocytes and
neurons. The inhibitory action of UBP141 on NMDA-activated currents in cortical astrocytes was
concentration-dependent (Fig.1C) with an IC50 of 2.29±0.37 µM (n=7). The IC50 for glial NMDARs was
close to IC50 values reported for the action of UBP141 on GluN1/GluN2C- and GluN1/GluN2D receptor-
mediated responses activated by saturating concentration of agonist (Morley et al., 2005). The IC50 for
the effect of UBP141 on NMDA-responses recorded in neurons was 19.8±3.4 µM (n=6); this value closely
agrees with IC50 values for GluN1/GluN2A and GluN1/GluN2B receptors (Morley et al., 2005).
We also tested the inhibitory action of another subunit-selective NMDAR antagonist – ifenprodil.
Incubation with 10 µM ifenprodil did not significantly affect the amplitude of NMDA-activated currents
in the cortical astrocytes (3±7% decrease; n=15, P > 0.05, one-population t-test; data not shown). In
contrast, the same concentration of ifenprodil inhibited the NMDA-response in cortical neurons by
58±11% (n=6, data not shown). The absence of notable effect of ifenprodil on NMDA-response in the
astrocytes indicates low level (if any) expression of GluN2B subunits. This result is slightly different from
our previous data (Lalo et al. 2006) obtained in younger mice (17-22 day-old), where we observed
partial (less than 50%) inhibition of NMDA receptors by 10 µM ifenprodil in the sub-population (about
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30%) of cortical astrocytes. The expression of both GluN2B and GluN2C subunits in the mouse cortical
astrocytes, also in younger age, has been reported by Schipke et al. (2001). The variation in the subunit
composition of astroglial NMDARs may be related to developmental changes, like it happens in neurons
where decrease in the expression of GluN2B and increase in the expression of GluN2C subunit have
been reported (Henson et al. 2010; Steinert et al. 2010). Also, the pathologically evoked expression of
GluN2B subunit might occur in the astrocytes in some cases after ischemic insults during tissue
preparation, as it has been observed by (Krebs et al. 2003).
Dramatic difference in the inhibitory action of UBP141 suggests different subunit composition of NMDA
receptors in cortical astrocytes and neurons, presumably lack of GluN2A and B subunits and
incorporation of GluN2C or D subunits in astroglial NMDARs. This hypothesis was supported by data on
the inhibitory action of memantine (Fig.2). Taking into account that action of memantine on NMDA
receptors depends on membrane potential and extracellular Mg2+ concentration (Wrighton et al., 2008;
Kotermanski and Johnson, 2009), we measured effect of memantine on astroglial and neuronal
receptors at physiological Mg2+ concentrations and membrane potentials at which these receptors
would likely be activated during physiological activity, correspondingly -80 mV and -40 mV. Pre-
application of 1 µM and 10 µM memantine decreased the amplitude of NMDA-evoked currents in the
astrocytes (Fig.2A) by 39 ± 12% and 72±7% respectively (n=7). However, neuronal responses to NMDA
(Fig.2B) were correspondingly inhibited by 7±11% and 46±10% (n=6).
Memantine exhibited different affinities for glial and neuronal NMDA receptors (Fig. 2C). The IC50 for the
action of memantine on NMDA-evoked currents in the cortical astrocytes was 2.19±0.18 µM (n=7) at -80
mV and 4.24±0.47 µM (n=5) at -40 mV. The weak voltage-dependence of the effect of memantine on
astroglial NMDA receptors was similar to the voltage-dependence of memantine action on GluN2D
receptors (Wrighton et al., 2008). The IC50 for the action of memantine on NMDA receptors in the
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cortical neurons was 10.8±0.55 µM (n=6) at -40 mV. It should be emphasized that the IC50 value for
NMDA-evoked currents in neurons obtained in our experiments is in very good agreement with the data
of Kotermanski and Johnson (2009) on the affinity of memantine to GluN2A and B subunits (constituent
subunits of the majority of neuronal NMDARs) in physiological concentrations of Mg2+. At the same
time, the IC50 for the action of memantine on NMDA-responses in astrocytes closely agrees with the
sensitivity of GluN2C/D-containing receptors (Kotermanski and Johnson, 2009).
Synaptically-activated currents in cortical astrocytes and neurons in situ
Results obtained in the acutely-isolated cells were corroborated by data on the pharmacological
sensitivity of NMDA receptor-mediated components of synaptic response in astrocytes and neurons in
brain slices. We performed voltage-clamp recordings from protoplasmic astrocytes and pyramidal
neurons in layer II/III of somato-sensory cortex of EGFP/GFAP mice (Nolte et al., 2001). The astrocytes in
acutely prepared brain slices were identified by green fluorescence and by their characteristic
electrophysiological signatures (see Methods).
Stimulation of neuronal afferents originating from layers IV-VI in presence of 100 µM picrotoxin
induced excitatory postsynaptic currents (EPSCs) in neurons and transmembrane ion currents in the
astrocytes (Fig.3, see also Lalo et al., 2006). Ion currents induced in the astrocytes were directly
associated with synaptic transmission because (i) treatment of slices with 1 M TTX completely
abolished glial responses, (ii) the amplitude of the glial response was stimulus-dependent in a manner
similar to the synaptic current evoked in the neighboring neurons and (iii) latency time of glial responses
was the same as latency of EPSCs (1.5-2.5 ms). Therefore, we identified astroglial responses as glial
synaptic currents (GSCs). As it has been shown before (Lalo et al., 2006), the major part of cortical GSC is
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mediated by glial NMDA receptors and glutamate transporters. Also, AMPA and P2X receptors can
participate in ionotropic signaling in cortical astrocytes (Lalo et al., 2006, Lalo et al., 2008). As we have
discussed previously (Lalo et al., 2006), astrocytic GSCs most likely result from both spill-out of
neurotransmitter from cortical synapses and ectopic release similarly to Bergmann glial cells (Matsui
and Jahr, 2004). Cortical astrocytes may also be a direct target of axon collaterals, like NG2+ glial cells in
hippocampus and cerebellum (Bergles et al., 2009).
To isolate NMDA receptor-mediated synaptic responses, recordings were carried out in presence
of CNQX (30µM), TFB-TBOA (1µM), DL-TBOA (30 µM) and PPADS (30µM). GSCs recorded under these
conditions in astrocytes at -80 mV had 10-90% rise time of 19.3±4.2 ms and decay time of 690±210 ms
(n=22); corresponding parameters of EPSCs recorded in neurons at -40 mV were 8.9±2.7 ms and
148±41 ms (n=22). Application of 30 µM D-AP5 inhibited the astrocytic GSCs and neuronal EPSCs
correspondingly by 96±7% and 93±9% (n=5, data not shown).
Similar to NMDA-activated currents in the acutely isolated cells, NMDA receptor-mediated synaptic
responses in astrocytes and neurons in situ exhibited different sensitivity to UBP141, ifenprodil and
memantine (Fig.3). Application of 3 µM UBP141 to cortical slices decreased the amplitude of astrocytic
GSCs by 58±6% (n=9), which recovered after washout of UBP141. However, consecutive application of
ifenprodil (10 µM) did not cause notable effect on astrocytic NMDA receptors (Fig.3A). In contrast,
application of 3 µM UBP141 decreased the amplitude of neuronal EPSCs only by 8±6% whereas
ifenprodil inhibited EPSCs by 63±9% (n=9).
Application of memantine confirmed the differential sensitivity of astrocytic and neuronal response to
NMDA. Memantine (1 µM and 10µM; Fig.3B) reversibly inhibited astrocytic GSCs by 41±8% and 81±6%
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respectively (n=8). However, 1 µM memantine had no effect on neuronal EPSCs (inhibition by 5±6%; P >
0.05, one-population t-test), whilst the 10 µM memantine inhibited EPSCs by 49±8% (n=8).
Theoretically, changes in the extracellular potassium concentration due to activity of neuronal
glutamate receptors might contribute to the inward current activated in the astrocytes by stimulation of
synaptic pathways. To verify that decrease in the GSCs amplitude observed in the above experiments
originated inhibition of astrocytic NMDA receptors, we perfused cortical astrocytes with 10 µM MK801
through the patch-pipette and applied D-AP5, UBP141 and memantine in the bath solution. Blocking of
astrocytic NMDA receptors with intracellular MK-801 caused slow but strong inhibition of GSC recorded
in presence of 100 µM picrotoxin, 50 µM CNQX and 30 µM PPADS in all 10 cells tested (Fig.3C). Neither
D-AP5 nor UBP141 had notable effect (n=6) on the residual GSCs resistant to intracellular MK-801; this
residual current was almost completely abolished after application of glutamate transporter blockers
TFB-TBOA (1 µM) and DL-TBOA( 30 µM). Similarly, memantine (10 µM) did not exhibit inhibitory action
on GSCs in presence of intracellular MK801 in all 4 astrocytes tested (data not shown).
These results confirm that action of UBP141 and memantine was due to direct inhibition of astrocytic
NMDA receptors. The small residual GSC (2±4%, n=10) remaining in presence of antagonists of NMDA
receptors and glutamate transporters may, however, be associated with redistribution of the
extracellular potassium in the vicinity of the astroglial membrane.
It is worth to note that inhibitory effects of UBP141 and memantine observed in astrocytes and neurons
in situ closely agree with data obtained in acutely isolated cells. Importantly, our results demonstrate
the feasibility of selective pharmacological modulation of NMDA receptor-mediated signalling in
neurons and astrocytes in physiological conditions.
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Functional properties and subunit composition of astroglial NMDARs
The above results suggest incorporation of GluN2C/D subunits in NMDA receptors expressed in cortical
astrocytes. Although GluN2C/D subunits have low affinity to Mg2+ than GluN2A/B, they are still blocked
by physiological concentrations (>0.5 mM) of Mg2+ (Qian and Johnson, 2006). In contrast, NMDARs
containing one or two GluN3 subunits were shown to have much lower sensitivity to Mg2+-block at
physiological concentrations (Sasaki et al. 2002; Tong et al. 2008; Henson et al., 2010). Incorporation of
GluN3 subunits, however, renders much lower calcium permeability to the NMDARs.
Taking into account the importance of Ca2+-signalling for the physiological activity of glial cells, we
evaluated Ca2+-permeability of astroglial NMDARs using the Goldman-Hodgkin-Katz theory (see
Methods). The reversal potential of NMDA-induced currents in the isolated cortical astrocytes in 2 and
20 mM extracellular Ca2+ was 0.92±0.89 mV and 7.5±2.4 mV (n=7) respectively (Fig.4). The
corresponding values for the neuronal NMDA-responses were 2.75±0.97 mV and 14.1±2.8 mV (n=6). The
permeability ratio PCa/PNa calculated from the reversal potential of NMDA-mediated current was 3.4 for
astrocytes and 7.5 for neurons.
The obtained PCa/PNa ratio for the NMDARs in cortical neurons agrees with data reported previously for
neuronal NMDARs and various heterologously expressed GluN1/GluN2 subunit combinations (Mayer
and Westbrook, 1987; Lino et al., 1990; Matsuda et al., 2003; Tong et al., 2008). On the other hand, our
evaluation of the relative Ca2+-permeability of astroglial NMDARs is very close to the results of recent
studies of GluN3 subunit-containing receptors (Sasaki et al., 2002; Matsuda et al., 2003; Tong et al.,
2008). It should be emphasized that even though the Ca2+-permeability of astroglial NMDA receptors is
lower compared to neuronal NMDARs, it is close to the permeability of other ionotropic receptors, like
neuronal nicotinic ACh receptors (PCa/PNa≈2.1-6.1)  or P2X1 (PCa/PNa =3.9) and P2X2 (PCa/PNa =2.2)
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receptors (Castro and Albuquerque, 1995; Evans et al., 1996; Fucile 2004) and is larger than the
permeability of Ca2+-permeable kainate (PCa/PNa=0.74) and AMPA (PCa/PNa≈0.5-1.7) receptors (Burnashev 
et al., 1996; Isa et al., 1996).
To verify that astroglial NMDA receptors can contribute to Ca2+-signalling, we measured elevation in the
cytosolic Ca2+ level simultaneously with transmembrane currents induced by application of glutamate
and NMDA to the isolated cortical astrocytes (Fig.5). Both NMDA and glutamate triggered significant rise
in the intracellular Ca2+ in the astrocytes. Amplitude of NMDA-induced Ca2+-transients reached
56.8±13.1 % (n=5) of Ca2+-transients activated by glutamate whereas amplitudes of NMDA-activated and
glutamate-activated transmembrane currents were almost similar. Application of 30 µM D-AP5
decreased the magnitude glutamate-activated Ca2+-transients (Fig.5) by 54.1±10.9% (n=5) and inhibited
transmembrane current even strongly (89.4±12.3%, n=5); transmembrane currents were eliminated by
further application of 30 µM NBQX (data not shown). These observations clearly indicate that
substantial component of glutamatergic Ca2+-signalling in cortical astrocytes is independent of NMDA
receptors. This component is most likely mediated by metabotropic glutamate receptors whose
participation in the astroglial Ca2+-signalling has been widely reported (Agulhon et al. 2008). Our data
also show that astroglial NMDARs, by virtue of their Ca2+-permeability and weak Mg2+-block, are capable
of delivering significant Ca2+-influx in cortical astrocytes. One could estimate the contribution of NMDA
receptors to the Ca2+-transients elicited by glutamate as 50-55%.
The combination of the lack of Mg2+-block together with lower Ca2+-permeability strongly suggests the
presence of the GluN3 subunit in glial NMDARs. Accordingly, the expression of pure di-heteromeric
GluN1/GluN3 receptors in cortical astrocytes cannot be ruled out a priori. The most characteristic
property of such receptors is a capability to be activated by application of glycine or D-serine in the
absence of glutamate. We found that glycine and D-serine acted as weak agonists, inducing inward
17
currents of much smaller amplitude than currents induced by NMDA or glutamate, in all 10 astrocytes
tested (Fig.6). This contrasts with the much higher potency of glycine that one would expect of pure
GluN1/GluN3 receptors (Chatterton et al., 2002; Henson et al., 2010). We also observed potentiation of
NMDA-activated currents in astrocytes by 10 µM D-serine (Fig.6), this is in contrast to the D-serine-
induced desensitization of GluN1/GluN3 receptors reported previously (Chatterton et al., 2002). On the
other hand, partial agonistic action of glycine in the cortical astrocytes closely agrees with data reported
for GluN1/ GluN2A/GluN3B tri-heteromeric receptors (Cavara and Hollmann, 2008).
To elucidate whether currents activated in the cortical astrocytes by glycine and D-serine were
mediated by di-heteromeric or tri-heteromeric receptors, we tested their sensitivity to NMDA receptor
antagonists. Weak block by classic NMDA antagonists is a characteristic feature of GluN1/GluN3
receptors whereas triplet GluN1/GluN2/GluN3 receptors can be blocked by antagonists targeting GluN2
subunits (Sasaki et al., 2002; Smothers and Woodward, 2010; Henson et al. 2010). MK-801 (10 µM),
memantine (10 µM) and UBP141 (10 µM) showed strong inhibitory action on the response of astrocytes
to glycine (Fig.7A) and D-serine (Fig. 7B). Inhibitory effects NMDAR antagonists on glycine and D-serine-
activated currents in the astrocytes did not differ significantly from their action on NMDA-activated
currents (Fig. 7C) indicating that di-heteromeric GluN1/GluN3 receptors bring a little contribution to
glutamatergic signalling in cortical astrocytes. Taken together, our results suggest that NMDA receptors
in cortical astroglia are assembled from GluN1, GluN2 and GluN3 subunits.
Discussion
Our results demonstrate striking difference in the properties of astrocytic and neuronal NMDA
receptors. Moreover, our findings provide several clues to identify the subunit composition of astroglial
NMDARs. There is no doubt that glial NMDARs contain two GluN1 subunits that are essential for
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trafficking to the membrane (Matsuda et al., 2003; Furukawa et al., 2005). In di- and tri-heteromeric
NMDARs, expression of certain types of GluN2A-D subunits confers sensitivity to selective antagonists,
such as D-AP5 or ifenprodi (Paoletti and Neyton, 2007). Hence, the most feasible explanation for the
high affinity of astroglial receptors to UBP141 and memantine and their low sensitivity to ifenprodil is
incorporation of GluN2C or GluN2D subunits. This hypothesis is also corroborated by very high potency
of glutamate and NMDA to astroglial NMDARs to (Lalo et al., 2006) which is close to the data reported
for recombinant GluN1/GluN2D receptors (Erreger et al., 2007).
At the same time, glial NMDA receptors have a very low sensitivity to Mg2+-block, as has been shown
already in (Lalo et al., 2006) and confirmed again in our present experiments. The only type of NMDA
subunits, insensitive to Mg2+ in physiological concentrations is the GluN3 subunit. The stoichiometry of
astroglial NMDARs might be different however, with incorporation of either one or two GluN3 subunits
(Henson et al., 2010). The functional expression of GluN1/GluN3 di-heteromeric receptors has been
suggested for cerebrocortical neurons (Chatterton et al., 2002); white matter oligodendrocytes have
been shown to express tri-heteromeric receptors (Karadottir et al., 2005; Burzomato et al. 2010).
The most peculiar feature of di-heteromeric GluN1/GluN3 receptors is their capability to be activated by
glycine and, arguably, D-serine with higher potency than glutamate that even gave rise to the
alternative term “excitatory glycine receptors” (Chatterton et al., 2002). These properties do not agree
with our observations: we did not observe a high potency of glycine and D-serine in the activation of
inward currents in the cortical astrocytes (Fig.6). We observed potentiation of NMDA-activated currents
by D-serine (Fig.6) not desensitization, which is not expected for GluN1/GluN3 assembly (Henson et al.,
2010). Furthermore, both NMDA-activated currents and responses to glycine and D-serine were
strongly inhibited by D-AP5 (Lalo et al., 2006), memantine (Fig.2,3) and MK-801 (Fig.4 and 7). Thus, the
19
pharmacological profile of NMDA-mediated responses in cortical astrocytes does not allow attributing
them purely to di-heteromeric GluN1/GluN3 receptors.
The only structural composition that can explain all pharmacological and functional properties of the
astroglial NMDARs we describe here is a tri-heteromer incorporating, in addition to two GluN1 subunits,
one of GluN2C or D subunit and one GluN3 subunit, rendering astroglial receptors much less sensitive to
Mg2+ but sensitive to UBP141, memantine and D-AP5 (Fig.1, 3 and 7). This suggestion is supported by
the weak Mg2+-block observed for tri-heteromeric GluN1/GluN2/GluN3 receptors (Sasaki et al., 2002;
Tong et al., 2008). It is also in line with evidence of expression of GluN2C, GluN2D and GluN3 subunits in
white matter oligodendrocytes (Karadottir et al., 2005; Burzomato et al., 2010).
It is worth to note that astroglial NMDARs showed lower sensitivity to Mg2+ -block than
GluN1/GluN2C/GluN3A receptors in oligodendrocytes (Karadottir et al., 2005; Burzomato et al., 2010).
This might be explained by incorporation of different splice variants of GluN1 and GluN2 subunits
and/or incorporation of GluN3B subunit. It has been shown that co-assembly of GluN3 with different
splice variants of GluN1 subunit can affect functional properties of di-heteromeric receptors (Cavara et
al., 2009; Smothers and Woodward, 2009). In particular, fractions of glycine-activated currents blocked
by Mg2+ in the receptor complexes assembled with GluN1-2b and GluN1-3b were much lower than in
the receptors containing other GluN1 variants (Cavara et al., 2009). Futhermore, degree of Mg2+ -block
of almost all isoforms of GluN1/GluN3B receptors (Cavara et al., 2009) was lower than Mg2+ -block
reported for GluN1/GluN3A receptors (Chatterton et al., 2002). It has also been reported recently that
splicing of GluN2A subunit can lead to loss of Mg2+-block (Endele et al., 2010). Thus, one could speculate
that co-assembly of GluN3A or GluN3B with different variants of GluN1 and GluN2 subunits might result
in the tri-heteromeric receptors with different sensitivity to Mg2+.
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Whatever is the particular mechanism explaining the variance in the Mg2+-sensitivity conferred by GluN3
subunits to glial triplet receptors, Mg2+-sensitivity is weak both in astrocytes and oligodendrocytes. This
may have similar physiological consequences: glial NMDARs can be activated at physiological resting
potentials and bring significant contribution to glial Ca2+-signalling despite their reduced Ca2+-
permeability. In view of possible implication of GluN3-containing receptors in brain injures (Henson et
al., 2010), the molecular structure of glial NMDARs is worth further investigation.
The other important finding of the present study is the difference in the affinity of glial and neuronal
NMDARs to memantine in physiological concentrations of Mg2+. The recent successes of memantine in
treatment of Alzheimer’s disease revived interest in the therapeutic use of NMDA antagonists (Lipton,
2006). Our findings strongly support the conclusions of Kotermanski and Johnson (2009) that neuronal
NMDARs can have much lower affinity to memantine in physiological conditions than was previously
thought and that the clinical effects of therapeutic doses of memantine are most likely related to its
action on GluN2C/D- rather than on GluN2A/B-containing receptors. Furthermore, our results suggest
that those GluN2C and D subunits, which might underlie the therapeutic effects of memantine, may be
mediated via astroglial NMDA receptors.
We have shown that the substantial difference in pharmacological and biophysical properties of
astroglial and neuronal NMDARs enables the selective modulation of synaptically-driven astrocytic
signalling. This may be very useful for elucidating the mechanisms of neuron-glia communications and
development of novel therapeutic agents specifically targeting glial signalling.
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Legends for Figures
Figure 1
The NR2C/D subunit-selective antagonist UBP141 differentially suppresses NMDA receptors in the astrocytes and
neurons. A, Representative traces illustrate the current activated by 50 µM NMDA in the acutely isolated cortical
layer II/III astrocyte before and after application of 3 and 10 µM of UBP141. B, action of the same concentrations
of UBP141 on current activated by 50 µM NMDA in a pyramidal neuron acutely isolated from the same cortical
slice. Note much weaker inhibitory effect of UBP141 in the neuron. C, the mean concentration-dependence of
UBP141 action in 7 astrocytes (IC50, 2.29±0.37 µM; Hill coefficient, 1.19±0.14) and 6 neurons (IC50, 19.8±3.4 µM;
Hill coefficient, 1.08±0.15). Amplitude of NMDA-response was normalized to control. Error bars represent SD.
Holding membrane potential was -80 mV in astrocytes and -40 mV in neurons.
Figure 2
Memantine differentially inhibits NMDA receptors in astrocytes and neurons. A, Representative traces illustrate
the NMDA-activated current recorded in the acutely isolated cortical layer II/III astrocyte before and after
application of 1 and 10 µM of memantine. B, action of the same concentrations of memantine on NMDA-
activated current in a pyramidal neuron acutely isolated from the same cortical slice. Note the much weaker
inhibitory effect of memantine in the neuron. C, the mean concentration-dependence of memantine action in 7
astrocytes at -80 mV (blue line, IC50, 2.19±0.18 µM; Hill coefficient, 1.01±0.07), in 5 astrocytes at -40 mV (red line,
IC50, 4.24±0.47 µM; Hill coefficient, 1.03±0.11) and in 6 neurons at -40 mV (IC50, 10.8±0.55 µM; Hill coefficient,
1.04±0.05). Error bars represent SD.
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Figure 3.
Action of UBP141 and memantine on the NMDA-receptor mediated synaptic currents in astrocytes and neurons
in situ. Transmembrane currents evoked in the astrocytes (glial synaptic currents; GSCs in red) and pyramidal
neurons (EPSCs, in blue) of layer II/III of mouse neocortex in situ by stimulation of neuronal afferents were
recorded in presence of 100 µM picrotoxin, 50 µM CNQX and 30 µM PPADS.
A, left panel shows the changes in the amplitude of astrocytic GSCs (red) and neuronal EPSCs (blue) following the
bath application of 3 µM UBP141 and 10 µM ifenprodil. Data are presented as mean±SD for 9 cells. B, changes in
the astrocytic GSCs (red) and neuronal EPSCs (blue) after application of 1 and 10 µM of memantine (mean±SD for
8 cells). Data shown in the panels A and B were measured in constant presence of glutamate transporters
antagonists TFB-TBOA, 1 µM and DL-TBOA, 30 µM. Each point in the time graphs shows the average amplitude
(relative to control) of 5 sequential currents. Illustrative examples of GSCs and EPSCs (average of 5 traces)
recorded as indicated, are shown in the right panels. Note the different inhibitory effects produced by UBP141,
ifenprodil and memantine in the astrocytes and neurons.
C, left panel shows the changes in the amplitude of astrocytic GSCs measured immediately after establishing
whole-cell recording using intracellular solution supplemented with 10µM MK-801 (mean±SD for 6 cells). D-AP5,
UBP141 and combination of TFB-TBOA (1 µM) and DL-TBOA( 30 µM) were applied to cortical slices as indicated.
Note that UPB141 did not decrease the amplitude of GSCs, when astrocytic NMDA receptors were inhibited by
intracellular MK-801, confirming that its action shown in panel A was due to inhibition of glial NMDA receptors.
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Figure 4.
Voltage-dependence of the currents mediated by NMDA receptors in astrocytes and neurons.
The upper panels show currents induced by rapid application of NMDA (50 µM, 1 s) recorded at the different
holding potentials in a cortical astrocyte (A) and pyramidal neuron (B) in 2 and 20 mM extracellular Ca2+ . The
lower panels shows the I–V curves constructed from 11 (astrocytes) and 6 (neurons) independent experiments.
The amplitudes of responses to NMDA were normalized to the value measured at -40 mV; data are presented as
mean±SD. Solid lines show the results of a best polynomial fit (least squares routine), intersection with zero
current axis gives the following values of reversal potential in 2 and 20 mM Ca2+OUT: 0.92 mV and 7.5 mV for
astrocytes and 2.75 and 14.1 mV for neurons. The permeability ratio PCa/PNa calculated in the framework of
extended Goldman-Hodgkin-Katz equation is 3.4 for astrocytes and 7.5 for neurons.
Figure 5
NMDA receptor-mediated Ca2+-signalling in cortical astrocytes.
A, An acutely isolated astrocyte was loaded with Fluo-3 via a somatic patch pipette. Fluorescent images were
recorded simultaneously with transmembrane currents evoked by application of 20 µM NMDA and 100 µM
glutamate in control and after consecutive application of 30 µM D-AP5. Representative images (left) and glial
currents (right, upper row) were recorded before (rest) and after application of agonist. Ca2+-transients (right,
lower row) represent the ΔF/F0 ratio averaged over the cell soma; scale bar is 10µm. Holding potential is -80 mV.
Transmembrane current activated by glutamate in control is mediated by NMDA and AMPA receptors and
glutamate transporters. The NMDA-component is eliminated by D-AP5. Ca2+-transient activated by glutamate in
control is mediated by metabotropic glutamate receptors, NMDA receptors and possibly by Ca2+-permeable
AMPA receptors. The Ca2+-transient activated by glutamate in presence of D-AP5 lacks the NMDA-receptor
mediated component. B, Pooled data (mean±SD for 5 astrocytes) of peak Ca2+-transients; the difference is
statistically significant with (*) P<0.01 and (**) P<0.005 (one-way ANOVA).
Note the significant contribution made by the NMDA receptors to glutamatergic Ca2+-signal in the astrocytes.
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Figure 6
Action of glycine and D-serine on astroglial and neuronal NMDA receptors.
(A, B) Representative responses activated in acutely-isolated cortical astrocyte and neuron by consecutive
application of 50 µM NMDA (no glycine added), 10 µM glycine, 10 µM D-serine and 20µM NMDA and D-serine
together.
(C) Pooled data (mean ± SD for 10 astrocytes and 7 neurons) of amplitude of current activated by glycine, D-serine
and NMDA and D-serine together; amplitudes were normalized to the amplitude of NMDA-activated current.
Recordings were made at a holding potential of -80 mV in the astrocytes and -40 mV in the neurons.
Note the weak agonist action of glycine and D-serine in the astrocytes.
Figure 7
Action of NMDA receptors antagonists on glycine and D-serine-activated currents in astrocytes.
(A) Representative responses activated in acutely-isolated cortical astrocyte by consecutive application of 50 µM
NMDA (no glycine added) and 10 µM glycine in control and presence of 10 µM MK801. NMDA and glycine were
applied in turn with 2 min interval. The gradual decline of astrocytic response is indicative of use-depended block;
block by MK801 established after 4th -5th round of application. Note the synchronous decrease in the amplitude of
both NMDA and glycine-activated currents.
(B) Representative responses activated in acutely-isolated cortical astrocyte by consecutive application of 50 µM
NMDA (no glycine added) and 10 µM D-serine in control and after application of 10 µM memantine. NMDA and
D-serine were applied in turn with 2 min interval.
(C) Pooled data (mean ± SD for 5 astrocytes) on the inhibitory effect of MK801, memantine and UBP141 on
astrocytic responses. Although glycine-activated currents exhibited less sensitivity to antagonists than NMDA-
activated currents, the difference was not statistically significant.
All recordings were made at a holding potential of -80 mV in presence of picrotoxin and strychnine.
.
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